Our results in breast cancer patients suggest that BRCA-positivity does not have a negative impact on oocyte yield, although higher FSH dose requirements do suggest lower ovarian response among these patients as compared to patients with BRCA-negative tumors. This evidence concerns the gene BRD2 and breast carcinoma.